115 related articles for article (PubMed ID: 29426755)
1. Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.
Sun A; Alshuaibi W; Petroni D; Skoda-Smith S; Goldberg MJ; Hale S
J Allergy Clin Immunol Pract; 2018; 6(5):1749-1751. PubMed ID: 29426755
[No Abstract] [Full Text] [Related]
2. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
[TBL] [Abstract][Full Text] [Related]
3. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.
Guvenir H; Dibek Misirlioglu E; Capanoglu M; Buyuktiryaki B; Unal O; Toyran M; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(4):1156-1157. PubMed ID: 28689831
[No Abstract] [Full Text] [Related]
4. Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.
Bekis Bozkurt H; Karakurt T; Cavkaytar O; Arga M
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):261-262. PubMed ID: 33992778
[No Abstract] [Full Text] [Related]
5. Successful Elosulfase Alfa Desensitization Protocol in a Patient With Morquio A Syndrome.
Díaz Vidal VC; Gillispie A; Aranda C; Anvari S
Pediatrics; 2022 Feb; 149(2):. PubMed ID: 35059725
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
Jones SA; Bialer M; Parini R; Martin K; Wang H; Yang K; Shaywitz AJ; Harmatz P
Pediatr Res; 2015 Dec; 78(6):717-22. PubMed ID: 26331768
[TBL] [Abstract][Full Text] [Related]
7. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.
Arroabarren E; Aznal E; Anda M; Sanchez-Valverde F
Pediatr Allergy Immunol; 2019 Jun; 30(4):491-494. PubMed ID: 30817035
[No Abstract] [Full Text] [Related]
8. Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.
Sosa AC; Kariuki B; Gan Q; Knutsen AP; Bellone CJ; Guzmán MA; Barrera LA; Tomatsu S; Chauhan AK; Armbrecht E; Montaño AM
J Clin Invest; 2020 Mar; 130(3):1288-1300. PubMed ID: 31743109
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
[TBL] [Abstract][Full Text] [Related]
10. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
[TBL] [Abstract][Full Text] [Related]
11. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
12. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.
Burton BK; Berger KI; Lewis GD; Tarnopolsky M; Treadwell M; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Genter F; Shaywitz AJ; Harmatz P
Am J Med Genet A; 2015 Oct; 167A(10):2272-81. PubMed ID: 26069231
[TBL] [Abstract][Full Text] [Related]
13. [Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy].
Politei J; Schenone AB; Guelbert N; Fainboim A; Szlago M
Arch Argent Pediatr; 2015 Aug; 113(4):359-64. PubMed ID: 26172013
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.
Tomatsu S; Montaño AM; Dung VC; Ohashi A; Oikawa H; Oguma T; Orii T; Barrera L; Sly WS
Mol Ther; 2010 Jun; 18(6):1094-102. PubMed ID: 20332769
[TBL] [Abstract][Full Text] [Related]
15. Is premedication a necessity before galsulfase replacement therapy?
Ercan N; Bostanci IB; Ozmen S; Ertugrul A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):200-2. PubMed ID: 27346567
[No Abstract] [Full Text] [Related]
16. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
Hendriksz CJ
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart FJ; Hughes DA; Matousek R; Hawley SM; Decker C; Harmatz PR
Mol Genet Metab; 2018 Feb; 123(2):127-134. PubMed ID: 29248359
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
Qi Y; Musson DG; Schweighardt B; Tompkins T; Jesaitis L; Shaywitz AJ; Yang K; O'Neill CA
Clin Pharmacokinet; 2014 Dec; 53(12):1137-47. PubMed ID: 25234648
[TBL] [Abstract][Full Text] [Related]
19. Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
Melton AC; Soon RK; Tompkins T; Long B; Schweighardt B; Qi Y; Vitelli C; Bagri A; Decker C; O'Neill CA; Zoog SJ; Jesaitis L
J Immunol Methods; 2017 Jan; 440():41-51. PubMed ID: 27789297
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
